ABAbsci Corporation ABSI · NASDAQ
$8.54 +3.52% (+$0.29)
- Market cap
- $1.47B
- Enterprise value
- $1.36B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 938.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -52.2%
- Gross margin
- -255.9%
- Net margin
- -7,756.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.28
- Free float
- 86.3%
About the company
Absci Corporation (ABSI) is an innovative biotechnology company headquartered in the USA, specializing in rapid protein development and production for the pharmaceutical and biotechnology industries. The company harnesses advanced artificial intelligence and automation technologies to expedite the protein design and engineering process, enabling swift response to market needs and drug development. Absci Corporation has emerged as a crucial partner for pharmaceutical firms seeking innovative and efficient approaches to drug development and therapies. Investors keen on advanced biotechnology and innovations in the pharmaceutical sector may recognize the potential for long-term growth and contributions to the healthcare industry in Absci Corporation (ABSI) shares.
Sector
Healthcare
Industry
Biotechnology
CEO
Sean McClain
Employees
140
Headquarters
Vancouver
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number